¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"gibberellin antagonist"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    1. ´ëÇ×Á¦, ±æÇ×Á¦ 2. ´ëÇ×±Ù
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°´ëÇ×Á¦, ¾Æµå·¹³¯¸°±æÇ×Á¦
  • competitive antagonist
    °æÀï´ëÇ×Á¦
  • contralateral antagonist
    ¹Ý´ëÂÊ´ëÇ×±Ù
  • direct antagonist
    Á÷Á¢´ëÇ×±Ù
  • dopaminergic antagonist
    µµÆÄ¹Î´ëÇ×Á¦, µµÆÄ¹Î±æÇ×Á¦
  • muscarinic antagonist
    ¹«½ºÄ«¸°´ëÇ×Á¦
  • narcotic antagonist
    ¸¶¾à´ëÇ×Á¦
  • neuromuscular antagonist
    ½Å°æ±Ù(À°)´ëÇ×Á¦
  • opioid antagonist
    ¾ÆÆíÀ¯»çÁ¦´ëÇ×Á¦
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    1.´ëÇ×Á¦, ±æÇ×Á¦, 2.´ëÇ×±Ù
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    ´ëÇ×Á¦, ¸Â¹öÆÀÁ¦
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°´ëÇ×Á¦
  • competitive antagonist
    °æÀï´ëÇ×¹°Áú
  • contralateral antagonist
    ¹Ý´ëÂÊ´ëÇ×±Ù
  • direct antagonist
    Á÷Á¢´ëÇ×±Ù
  • dopaminergic antagonist
    µµÆÄ¹Î´ëÇ×Á¦, µµÆÄ¹Î¸Â¹öÆÀÁ¦
  • ipsilateral antagonist
    °°ÀºÂÊ´ëÇ×±Ù
  • muscarinic antagonist
    ¹«½ºÄ«¸°´ëÇ×Á¦
  • narcotic antagonist
    ¸¶¾à´ëÇ×Á¦
  • neuromuscular antagonist
    ½Å°æ±ÙÀ°´ëÇ×Á¦
  • opioid antagonist
    ¾ÆÆíÀ¯»ç¹°Áú´ëÇ×Á¦
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • H2 receptor antagonist
    H2 ¼ö¿ëü ±æÇ×Á¦µé
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • alpha-adrenergic antagonist
    ¾ËÆÄ¾Æµå·¹³¯¸°±æÇ×Á¦
  • androgen antagonist
    ³²¼ºÈ£¸£¸ó ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦(ÑÏù÷ð¥)
  • antagonist
    ±æÇ×Á¦, ±æÇ×¹°Áú, ±æÇ×±Ù, ±æÇ×¾à.
  • heavy metal antagonist
    Á߱ݼӱæÇ×¾à(̡˻ËÛ˻̰Ëâ).
  • heavy metal antagonist
    Á߱ݼӱæÇ×¾à(ñìÐÝáÕÑÏù÷å·).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adrenergic antagonist
    ¾Æµå·¹³¯¸° ±æÇ×¹°Áú
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°¼º ±æÇ×Á¦
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • alpha-adrenergic antagonist
    ¾ËÆÄ¾Æµå·¹³¯¸°±æÇ×Á¦
  • androgen antagonist
    ³²¼ºÈ£¸£¸ó ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦(ÑÏù÷ð¥)
  • antagonist
    ±æÇ×Á¦, ±æÇ×¹°Áú, ±æÇ×±Ù, ±æÇ×¾à.
  • antagonist
    ±æÇ×Á¦
  • associated antagonist
    °ø¾×±æÇ×¹°Áú.
  • benzodiazepine receptor antagonist(s)
    º¥Á¶´ÙÀ̾ÆÁ¦ÇÉ ¼ö¿ëü ±æÇ×Á¦
  • beta-adrenergic antagonist
    º£Å¸ ¾Æµå·¹³¯¸°¼º ÀúÇØÁ¦
  • calcium antagonist
    Ä®½·±æÇ×Á¦.
  • calcium channel antagonist,blocker
    Ä®½·Åë·Î ±æÇ×Á¦( -÷×ÖØ ÑÏù÷ð¥),Â÷´ÜÁ¦(ó´Ó¨ð¥).
  • competitive antagonist
    °æÀï±æÇ×¹°Áú(¡­Úªòõ).
  • contralateral antagonist
    ¹Ý´ëÃø±æÇ×±Ù
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gibberellin antagonist
    Áö¹ö·¼¸° ±æÇ×Á¦(ÑÏù÷ð¥)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gibberellin
    Áö¹ö·¼¸°
  • antagonist
    ±æÇ×Á¦(ÑÏù÷ð¥)
  • cholinergic antagonist
    Äݸ°±æÇ×Á¦(ÑÏù÷ð¥)
  • irreversible antagonist
    ºñ°¡¿ª ±æÇ×Á¦(ުʦæ½ÑÏù÷ð¥)
  • metabolic antagonist
    ´ë»ç¼º ±æÇ×Á¦(ÓÛÞóàõÑÏùòð¥))
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    ±æÇ×Á¦, ±æÇ×¹°Áú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
antag antagonist
CA anterior commissure [Lat. commissura anterior]; calcium antagonist; California [rabbit]; cancer; Can...
FAA folic acid antagonist; formaldehyde, acetic acid, alcohol
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
GA gibberellin A
Ant Antagonist
CA calcium antagonist
GnRH-A GnRH antagonist
H2-RA Histamine-2 receptor antagonist
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • 5-HT1 receptor antagonist
    5-HT1 ¼ö¿ë±â ±æÇ×Á¦
    ÀÏÂïÀÌ 5-hydroxytry
  • alpha adrenergic antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸° ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦, ±æÇ× ¹°Áú, ±æÇ×±Ù, ±æÇ× ¾à
    ¹Ý´ë¾î=agonist. µ¿±Ù±ºÀ̳ª ÁÖµÈ ¿îµ¿±Ù¿¡ ¹Ý´ëµÇ´Â ±â´ÉÀ» ÇÏ´Â ±ÙÀ°. ¾à¸®Çп¡¼­´Â ´Ù¸¥ ¾à¹°ÀÇ È¿´ÉÀ» °¨¼Ò½ÃŰ´Â ¾à¹°À̳ª µ¿ÀÏÇÑ ¼ö¿ë±â¸¦ ÀÚ±ØÇÏ¿© »ý¼ºÇÏ´Â ¹°ÁúÀ» ÀǹÌÇÑ´Ù. ´Ù¸¥ ¾à¹°, ¹°ÁúÀÇ ÀÛ¿ëÀ» »ý¹°ÇÐÀû ¹ÝÀÀÀ» À¯µµÇÏÁö ¾Ê°í ¼¼Æ÷ ¸®¼ÁÅÍ¿¡ °áÇÕÇÏ¿©, °¨¾à ¶Ç´Â ¹«È¿·Î ÇÏ´Â ¾à¹°, ¹°Áú.
  • antagonist tooth
    ´ëÇÕÄ¡
  • competitive antagonist
    °æÀï ±æÇ× ¹°Áú
  • enzymic antagonist
    È¿¼Ò ±æÇ×Á¦
  • folic acid antagonist
    ¿±»ê ±æÇ×Á¦
  • hormone antagonist
    Ç×È£¸£¸ó ¾à, Ç×È£¸£¸ó ¹°Áú
  • metabolic antagonist
    ´ë»ç ±æÇ×Á¦
  • narcotic antagonist
    ¸¶¾à ±æÇ×Á¦
  • neuromuscular antagonist
    ½Å°æ±Ù ±æÇ×Á¦
  • pyrimidine antagonist
    ÇǸ®¹Ìµò ±æÇ×Á¦
  • serotonin antagonist
    ¼¼·ÎÅä´Ñ ±æÇ×Á¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
gibberellin <protein> Plant growth substance (phytohormone) involved in promotion of stem elongation, mobilisation of food reserves in seeds and other processes. Its absence results in the dwarfism of some plant varieties. Chemically all known gibberellins are gibberellic acids.
(18 Nov 1997)
gibberellin 2beta, 3beta-hydroxylase <enzyme> Bifunctional enzyme from pumpkin endosperm; catalyses all 3 beta hydroxylations of c19 and c20 gibberillins and all 2 beta hydroxylations of c20 gibberellins; genbank u63650
Registry number: EC 1.14.99.-
Synonym: cm3h gene product, ga 2beta, 3beta-hydroxylase
(26 Jun 1999)
gibberellin 3beta-hydroxylase <enzyme> Product of le (stem length) gene of pea (pisum sativum) described by mendel; genbank u93210
Registry number: EC 1.14.99.-
Synonym: ga4 gene product, le gene product, ga 3beta-hydroxylase
(26 Jun 1999)
gibberellin 7-oxidase <enzyme> A 2-oxoglutarate-dependent dioxygenase from pumpkin endosperm, involved in gibberellin biosynthesis; 314 amino acids, mw 35.7 kD; genbank u61386
Registry number: EC 1.14.11.-
Synonym: ga 7-oxidase, ga-7-dioxygenase
(26 Jun 1999)
aldosterone antagonist An agent that opposes the action of the adrenal hormone aldosterone on renal tubular mineralocorticoid retention; these agents, e.g., spironolactone, are useful in treating the hypertension of primary hyperaldosteronism, or the sodium retention of secondary hyperaldosteronism.
(05 Mar 2000)
antagonist <pharmacology> A substance that tends to nullify the action of another, as a drug that binds to a cell receptor without eliciting a biological response.
Origin: Gr. Antagonistes = an opponent
(18 Nov 1997)
associated antagonist One of two muscles or groups of muscles which pull in nearly opposite directions, but which, when acting together, move the part in a path between their diverging lines of action.
(05 Mar 2000)
beta-adrenoreceptor antagonist A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable.
Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker.
(05 Mar 2000)
calcium antagonist calcium channel-blocking agent
calcium channel antagonist <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools.
Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent.
(12 May 2002)
mixed opioid agonist-antagonist <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type.
(13 Nov 1997)
competitive antagonist An antimetabolite.
(05 Mar 2000)
muscarinic antagonist Drugs which bind with muscarinic cholinergic receptors but do not activate them, thus preventing access to acetylcholine; examples include atropine, scopolamine, propantheline, and pirenzepine.
(05 Mar 2000)
H2 antagonist <pharmacology> A class of anti-ulcer medication which work through the inhibition of basal and nocturnal gastric acid secretion by competitive inhibition of the action of histamine at histamine H2 receptor sites on the parietal cells.
Drugs of this type block gastric acid secretion and are therefore clinically useful in treating duodenal ulcers.
Examples include cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid) and ranitidine (Zantac).
(27 Sep 1997)
insulin antagonist Something that opposes or fights the action of insulin. Insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it, therefore, glucagon is an antagonist of insulin.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gibberellin
    Áöº£·¼¸°(°íµî ½Ä¹°ÀÇ »ýÀå È£¸£¸ó)
  • antagonist
    Àû´ë
  • antagonist
    Àû´ëÀÚ;´ë¸³ÀÚ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á